The following is from a September 9, 2011 Reuter's update with reporting by Tom Hals; additional reporting by Rans Pierson in New York; and editing by Derek Caney:
Delaware District Court judge Sue Robinson ruled on Thursday that the generic drugmakers failed to prove Allergan's patents protecting Lumigan were invalid and found the generic forms infringed those patents.
Barr Laboratories Inc, a unit of Teva, and Novartis (NOVN.VX) (NVS.N) unit Sandoz filed abbreviated new drug applications (ANDA) in 2009 to make a generic version of the drug. Allergan sued, claiming patent infringement.
Lumigan has annual global sales of about $650 million, making it one of Allergan's biggest prescription eye medicines.
Access the update here.